Recordati (REC) ICR Healthcare's 12th Annual Healthcare Conference summary

Keynote interview: Leadership and strategy in rare disease pharma

• CEO discussed transition from family-led to empowered management, emphasizing innovation and internationalization.

• Rare disease business is the fastest-growing segment, with U.S. as the largest market and a focus on unmet medical needs.

• Recent acquisition (Enjaymo) expected to accelerate rare disease growth, aiming for a 50/50 revenue split with traditional business.

• Manufacturing strategy prioritizes in-house production in Europe for supply chain resilience, with 40% outsourced.

• Expansion in China is cautious, focusing on commercial partnerships and avoiding technology transfer.

Panel: Strategic options for biotech companies

• Hypothetical scenario explored trade-offs between licensing, M&A, IPO, and private financing for a VC-backed obesity platform.

• Panelists stressed the importance of maintaining optionality, avoiding early exclusivity, and running parallel processes.

• Divided boards and investor alignment were highlighted as key challenges in decision-making.

• Market conditions in 2025 were described as buoyant, with IPO windows open and increased M&A activity.

• Final consensus leaned toward maximizing value through competitive processes and careful risk assessment of deal structures.

Industry trends and investor perspectives

• Investors are focused on management quality, science, and macroeconomic factors, with activism expected to rise.

• Hot investment areas for 2025 include cardiovascular, I&I, radiopharma, psychiatry, and neurology.

• Emphasis on building relationships early in deal-making and the importance of agility in rare disease commercialization.